Download "Site-directed antibodies targeting driver mutations of the KRAS protein"

Front cover

Explore how our recombinant antibody technology was used to develop highly specific antibodies against the KRAS G12D mutation—one of the most common oncogenic drivers in cancer. This publication highlights the development and performance of our KRAS G12D Mutant Recombinant Antibody [29B] (ATM00004), with data demonstrating its binding specificity and utility in key applications.

Download the full publication to learn:

  • How site-directed antibody design enables mutant-specific detection

  • The binding performance of clone 29B across ELISA, WB, and ICC

  • Why researchers are turning to recombinant tools for targeting hard-to-hit proteins like KRAS